Q3 FY23 Earnings Presentation

Key product approvals Last 12 months: ~150 product approvals in key geographies¹ Interstim TM X System (U.S.) LigaPASSTM 2.0 Ligament Augmentation Onyx Frontier™ drug-eluting stent (U.S.) System (U.S.) Onyx Frontier™ drug-eluting stent (Europe) Pediatric Indication: FreezorTM & Freezor™ Xtra Cryoablation Catheters (U.S.) Nellcor™ OxySoft™ neonatal-adult SpO2 sensor (U.S.) Guidance & ESG Appendix Table of Executive Portfolio Financial Contents Summary Highlights Highlights Assumptions Radiant TM balloon- expandable covered stent (Europe) IN.PactTM 018 DCB (U.S.) UNIDTM Spine Analyzer (U.S.) RespArray™ patient monitor (U.S.) Nexpowder™ Hugo™M Endoscopic Hemostasis System (U.S.) Robotic Assisted Surgery Platform (Japan) Pediatric Indication: LINQ ||TM Insertable Cardiac Monitor (U.S.) Left Bundle Branch Expansion: SelectSureTM MRI SureScan® Model 3830 cardiac lead (U.S) MiniMed™ 780G system (Canada) Ligasure ™ XP Maryland Jaw Sealer/Divider (U.S) Ô ||| 0 || 0 || 0 || - ||| Ô TÔ || 0 || 0 || 0 || 0 || 0 || - ||| 0 | 0 | 0 Q4 FY22 Note: Relative positioning is not intended to signify relative timing 1) Includes U.S., EU, Japan and China. Does not include all indication or partner approvals, though select additional approvals are displayed 8 Q3 FY23 Earnings Presentation | February 21, 2023 Q3 FY23 Medtronic

View entire presentation